A detailed history of Tower Research Capital LLC (Trc) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 605 shares of COGT stock, worth $5,378. This represents 0.0% of its overall portfolio holdings.

Number of Shares
605
Previous 22,364 97.29%
Holding current value
$5,378
Previous $188,000 96.81%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.24 - $11.48 $179,294 - $249,793
-21,759 Reduced 97.29%
605 $6,000
Q2 2024

Aug 13, 2024

BUY
$6.01 - $9.04 $118,517 - $178,268
19,720 Added 745.84%
22,364 $188,000
Q1 2024

May 15, 2024

SELL
$4.38 - $9.02 $162,988 - $335,652
-37,212 Reduced 93.37%
2,644 $17,000
Q4 2023

Feb 13, 2024

BUY
$4.06 - $10.08 $149,972 - $372,345
36,939 Added 1266.34%
39,856 $234,000
Q3 2023

Nov 14, 2023

BUY
$9.69 - $13.34 $9,486 - $13,059
979 Added 50.52%
2,917 $28,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.24 $10,756 - $14,458
-1,092 Reduced 36.04%
1,938 $22,000
Q1 2023

May 09, 2023

SELL
$10.04 - $15.5 $883 - $1,364
-88 Reduced 2.82%
3,030 $33,000
Q4 2022

Feb 10, 2023

SELL
$10.65 - $14.84 $2,460 - $3,428
-231 Reduced 6.9%
3,118 $36,000
Q3 2022

Nov 10, 2022

BUY
$9.39 - $16.99 $3,032 - $5,487
323 Added 10.67%
3,349 $50,000
Q2 2022

Aug 15, 2022

BUY
$3.92 - $9.73 $2,363 - $5,867
603 Added 24.89%
3,026 $27,000
Q1 2022

May 12, 2022

BUY
$5.31 - $8.7 $5,209 - $8,534
981 Added 68.03%
2,423 $18,000
Q4 2021

Feb 14, 2022

SELL
$7.51 - $10.81 $10,341 - $14,885
-1,377 Reduced 48.85%
1,442 $13,000
Q3 2021

Nov 15, 2021

SELL
$5.99 - $9.14 $32,016 - $48,853
-5,345 Reduced 65.47%
2,819 $24,000
Q2 2021

Aug 16, 2021

BUY
$7.82 - $9.3 $63,842 - $75,925
8,164 New
8,164 $66,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $585M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.